TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03380026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Apply up to three times daily on select lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valchlor 0.016 % Topical Gel
Description: Apply valchlor nightly on select lesions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valchlor 0.016 % Topical Gel
Description: Apply valchlor nightly on select lesions.
Study: NCT03326869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raindrop Near Vision Inlay
Description: The Raindrop Near Vision Inlay was approved by the US FDA in June of 2016 for the improvement of near vision in presbyopic emmetropes. Raindrop is a clear device made of a hydrogel material and resembles a microscopic contact lens; it is the first implantable device that changes the shape of the cornea to correct the refractive errors that cause near vision problems.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Raindrop Near Vision Inlay
Description: The Raindrop Near Vision Inlay was approved by the US FDA in June of 2016 for the improvement of near vision in presbyopic emmetropes. Raindrop is a clear device made of a hydrogel material and resembles a microscopic contact lens; it is the first implantable device that changes the shape of the cornea to correct the refractive errors that cause near vision problems.
Study: NCT03043846

Intervention type: OTHER
Intervention: Follow-up every 3 months during 1 year (data collection in eCRF)

Intervention type: OTHER
Intervention: Follow-up every 3 months during 1 year (data collection in eCRF)

Intervention type: OTHER
Intervention: Follow-up every month to follow the pre-defined strategy
Study: NCT02420795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt/ERK Inhibitor ONC201
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01630941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: denosumab
Description: Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: denosumab
Description: Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval
Study: NCT03716336

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic exercise
Description: aerobic exercise were performed on treadmill. For 20 minutes. All patients in both groups (A,B) had attended the program of a resistance exercises and followed by aerobic exercise for 8 weeks in form of 20 minutes walking on the treadmill without inclination.

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic exercise
Description: aerobic exercise were performed on treadmill. For 20 minutes. All patients in both groups (A,B) had attended the program of a resistance exercises and followed by aerobic exercise for 8 weeks in form of 20 minutes walking on the treadmill without inclination.
Study: NCT02955108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Distractive Auditory Stimuli
Description: Participants will wear headphones with no music playing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Distractive Auditory Stimuli
Description: Participants will wear headphones with no music playing
Study: NCT03017339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Functional Exercise

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Low Level Laser Therapy
Description: Low Level Laser Therapy with the device off
Study: NCT03038971

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Dose Level 1
Description: Short and Tall Ragweed Mix

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Dose Level 2
Description: Short and Tall Ragweed Mix

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Saline with 0.4% Phenol
Study: NCT03578926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fanfilcon A toric lens
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A toric lens
Description: contact lens
Study: NCT03350971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality training
Description: training with Wii games, ergometer exercise, ambulation, standing exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: chest physical therapy exercises
Study: NCT03563755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification
Description: CBM-Attention (CBM-A) will be used with the aim of ameliorating negative cognitive biases in attention by redirecting attention towards positive social stimuli (accepting faces). Similarly CBM-Interpretation (CBM-I) will be used to ameliorate negative interpretation bias, by reinforcing benign outcomes of ambiguous social scenarios. Implementation intentions will be used to guide participants in planning new ways to face difficult social situations involving the risk of social rejection/criticism. Participants will continue to receive their usual treatment.
Study: NCT01971671

Intervention type: OTHER
Intervention: no intervention.
Study: NCT00393991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/formoterol fumarate 100/10
Description: FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study: NCT02577367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: Administer Levothyroxine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Administer Levothyroxine
Study: NCT04629638

Intervention type: OTHER
Intervention: Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores
Description: The results will be compared with the results of covid-negative pregnant women who gave birth in the same period.

Intervention type: OTHER
Intervention: Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores
Description: The results will be compared with the results of covid-negative pregnant women who gave birth in the same period.
Study: NCT01719016

Intervention type: PROCEDURE
Intervention: Cardiac PET, Coronary catheterization
Description: Patients would under go a Cardiac rest and stress PET scan and include the following drug administration:~1. N-13 Ammonia radionuclide - Two doses, 10 mCi for rest, 20 mCi for stress~2. Lexiscan - stress agent for PET scan~Patients would also undergo Coronary catheterization including the following drug administration and device usage:~1. Combowire to obtain pressure and flow readings on Combomap machine (Volcano Therapeutics, CA).~2. Adenosine - stress agent during catheterization, 140 ug/Kg/min
Study: NCT00393991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 100
Description: Fluticasone 100ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol fumarate 10
Description: Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study: NCT02653313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parvovirus H-1 (H-1PV)
Description: Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer.~The total dose levels are: 1E09, 5E09 and 1E10 pfu.
Study: NCT03209362

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SI-613
Description: SI-613 will be repeated intra-articularly administered.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be repeated intra-articularly administered.
Study: NCT04241172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Immersive Virtual Reality (HIVR)
Description: the HIVR exercises will be performed using Nirvana system, a medical device based on virtual reality specifically designed to support motor rehabilitation, by projecting aquatic scenarios on the floor that simulates the movement and the noise of the water due to the motor exercise execution by the patient. In particular, the following virtual reality scenarios will be used:~* Swimming pool: the environment represents a swimming pool (water and edge). The patient must perform exercises by moving the lower limbs while sitting on a chair. The virtual environment gives the sensation of having the lower limbs immersed in water above the knees;~* Water metal: the environment gives the feeling of being immersed in water up to the waist. The subject interacts with the virtual water performing walking exercises and receiving a visual and auditory biofeedback.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Hydrotherapy (TH)
Description: The TH group exercises will be performed in a swimming pool suitable for hydrotherapy treatments. In particular, patients will perform:~* exercises with a patients sitting on the swimming pool edge with lower limb immersed in the water;~* flexion-extension of the knee;~* leg and hip circling;~* flexion-extension of the ankle;~* triple flexion;~* water walking exercises.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Rehabilitation (TR)
Description: The TR group exercises will be performed in the gym with a physiotherapist. In particular, patients will perform:~* exercises with a patient sitting on a chair (3 minutes per exercise):~* flexion-extension of the knee;~* leg and hip circling;~* flexion-extension of the ankle;~* triple flexion;~* walking (with and without aids).
Study: NCT02382757

Intervention type: DRUG
Intervention: insulin human
Description: Children will receive conventional treatment with human insulin according to standard medical practice.
Study: NCT02840513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone app/CO self-monitoring
Description: Smartphone app and carbon monoxide self-monitoring (personal device)
Study: NCT04381572

Intervention type: BEHAVIORAL
Intervention: High fidelity simulation training
Description: At the beginning of scheduled classes in the simulation center, students were placed sitting at rest for 30 min. In each team a leader was chosen. Other team members were also assigned detailed functions. Before starting the scenario, participants were oriented for 10 -15 minutes by a physician instructor about the simulation room setup and manikin features. The simulated scenarios were performed using a high fidelity computer-based manikin simulator, with the possibility of remote control of vital signs. All medications and equipment required during the clinical scenarios were available. The scenario used was prepared and validated by experienced simulation instructors. All student groups were given the same standardized scenario.
Study: NCT01313078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated L-Asparaginase
Description: Pegaspargase 2000 IU/m\^2 intramuscular or intravenously every 2 weeks
Study: NCT05369624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation home-based program intervention group (PRHP)(IG)
Description: The strength training program included upper and lower limb exercises, initially with no weights but progressively adding weights once a week depending on symptoms, in 2 sets with 6-8 repetitions, for at least 5 days a week. The exercises recommended were the 'hanger' (which exercises the latissimus dorsi muscle), 'butterfly' (pectoralis major muscle), 'neck press' (triceps brachii and deltoids), leg flexion (biceps femoris and gastrocnemius) and leg extension (quadriceps femoris).~As resistance training, patients could choose between walking or cycling 3 to 5 days per week, for at least 20 minutes, increasing the duration of the exercise weekly, depending on their symptoms
Study: NCT03073213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered as subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered as subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered as subcutaneous (SC) injection
Study: NCT03035344

Intervention type: OTHER
Intervention: Metabolome study
Description: Metabolome study in ALL patients compared to healthy controls

Intervention type: OTHER
Intervention: Metabolome study
Description: Metabolome study in ALL patients compared to healthy controls
Study: NCT01501864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School Support Intervention
Description: Comprehensive school support is provided that includes payment of school fees, school uniform, and a nurse researcher who monitors attendance and addresses problems that may lead to school absence and dropout.
Study: NCT00727766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Study: NCT03716336

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: diet restriction
Description: All participants in both groups (A,B) were instructed to follow a moderate restricted diet limited to (1800-2000) kcal/ day under supervision of a certified dietician. The diet contained: Protein and fibers: 20% carbohydrate: 50-60%, fat: low 20%.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: diet restriction
Description: All participants in both groups (A,B) were instructed to follow a moderate restricted diet limited to (1800-2000) kcal/ day under supervision of a certified dietician. The diet contained: Protein and fibers: 20% carbohydrate: 50-60%, fat: low 20%.
Study: NCT01222039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.
Description: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Low dose: 1 x10e6 / Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.
Description: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Low dose: 1 x10e6 / Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.
Description: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. High dose: 3 x10e6/Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.
Description: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. High dose: 3 x10e6/Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
Study: NCT02489695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: axitinib 10mg twice a day
Study: NCT01149707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR 0110 Rectal Enema 250 mg
Description: PUR 0110 Rectal Enema 250 mg, once-daily, intrarectally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR 0110 Rectal Enema 500 mg
Description: PUR 0110 Rectal Enema 500 mg, once-daily, intrarectally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR 0110 Rectal Enema 1000 mg
Description: PUR 0110 Rectal Enema 1000 mg, once-daily, intrarectally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Enema
Description: Placebo Enema, once-daily, intrarectally
Study: NCT02250430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204
Description: Applied topically twice a day on days 1, 2 and 3 to left and right cheeks
Study: NCT00727766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Study: NCT04616339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-06882961 100 mg
Description: PF-06882961 100 mg will be provided in 5 different oral formulations A, B, C, D, and E. Cohort 1 is a randomized, open-label, single dose, 4-period, 4-sequence, crossover design where the first 2 periods are cross-over (Formulations A and B) and the second 2 periods are crossover (Formulations C and D).~Cohort 2 is a randomized, open-label, single dose, 2-period, 2 sequence, crossover design (Formulations A and E)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-06882961 100 mg
Description: PF-06882961 100 mg will be provided in 5 different oral formulations A, B, C, D, and E. Cohort 1 is a randomized, open-label, single dose, 4-period, 4-sequence, crossover design where the first 2 periods are cross-over (Formulations A and B) and the second 2 periods are crossover (Formulations C and D).~Cohort 2 is a randomized, open-label, single dose, 2-period, 2 sequence, crossover design (Formulations A and E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 100 mg
Description: PF-06882961 100 mg will be provided in 5 different oral formulations A, B, C, D, and E. Cohort 1 is a randomized, open-label, single dose, 4-period, 4-sequence, crossover design where the first 2 periods are cross-over (Formulations A and B) and the second 2 periods are crossover (Formulations C and D).~Cohort 2 is a randomized, open-label, single dose, 2-period, 2 sequence, crossover design (Formulations A and E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 100 mg
Description: PF-06882961 100 mg will be provided in 5 different oral formulations A, B, C, D, and E. Cohort 1 is a randomized, open-label, single dose, 4-period, 4-sequence, crossover design where the first 2 periods are cross-over (Formulations A and B) and the second 2 periods are crossover (Formulations C and D).~Cohort 2 is a randomized, open-label, single dose, 2-period, 2 sequence, crossover design (Formulations A and E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 100 mg
Description: PF-06882961 100 mg will be provided in 5 different oral formulations A, B, C, D, and E. Cohort 1 is a randomized, open-label, single dose, 4-period, 4-sequence, crossover design where the first 2 periods are cross-over (Formulations A and B) and the second 2 periods are crossover (Formulations C and D).~Cohort 2 is a randomized, open-label, single dose, 2-period, 2 sequence, crossover design (Formulations A and E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 100 mg
Description: PF-06882961 100 mg will be provided in 5 different oral formulations A, B, C, D, and E. Cohort 1 is a randomized, open-label, single dose, 4-period, 4-sequence, crossover design where the first 2 periods are cross-over (Formulations A and B) and the second 2 periods are crossover (Formulations C and D).~Cohort 2 is a randomized, open-label, single dose, 2-period, 2 sequence, crossover design (Formulations A and E)
Study: NCT03573505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00011
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT03666559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Chemotherapy
Study: NCT01214915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagrelide Hydrochloride
Description: Subjects will be started at 1.0 mg per day and titrated as necessary.
Study: NCT03358745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard meal, bread/butter as starter
Description: Reference lunch. Bread and butter are eaten during the first 15 min. Soup, cheese and salad are eaten within the following 15 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard meal with soup as starter
Description: Lunch meal in which soup is eaten during the first 15 min. Bread, butter, cheese and salad are eaten within the following 15 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard meal with cheese as starter
Description: Lunch meal in which cheese is eaten during the first 15 min. Bread, butter, soup and salad are eaten within the following 15 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard meal with salad as starter
Description: Lunch meal in which salad is eaten during the first 15 min. Bread, butter, soup and cheese are eaten within the following 15 min.
Study: NCT01549106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm; ketoconazole drug interaction study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm
Study: NCT01996332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg/day until progressive disease or unacceptable toxicity